Evidence map›Paper›PMID 36672178›Full record

ArticleCells2023

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β

Joseph Antony Jude, Ian Dainty, Nikhil Karmacharya, William Jester, Reynold Panettieri

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Joseph Antony JudePharmacology & Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Ian DaintyBioscience, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Molndal, Sweden.
Nikhil KarmacharyaRutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
William JesterRutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Reynold PanettieriRutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Rutgers, The State University of New Jersey · USAstraZeneca (Sweden) · SE

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

Bronchodilators and anti-inflammatory agents are the mainstream treatments in chronic obstructive and pulmonary disease (COPD) and asthma. The combination of β

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAdrenergic AgonistsHistamineHumansLungMuscarinic AntagonistsPropranololReceptors, MuscarinicAdrenergic AgonistsBronchodilator AgentsHistamineMuscarinic AntagonistsPropranololReceptors, Muscarinicasthmahuman airwayshuman precision-cut lung slicemuscarinic antagonist and β2AR agonistnavafenterol

Identifiers

PMID36672178
PMCPMC9856842
OpenAlexW4313826074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.